Actionable Mutations in NSCLC
Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).
Clinical Pearls
Thomas J. Lynch, MD, Richard Sackler and Jonathan Sackler Professor of Medicine (Medical Oncology), director, Yale Cancer Center, physician-in-chief, Smilow Cancer Hospital at Yale-New Haven, Giant of Lung Cancer Care, discusses actionable mutations in non-small cell lung cancer (NSCLC).
- An actionable mutation can be found in 40-45% of patients with NSCLC
- Second- and third-generation EGFR inhibitors could have greater efficacy than some older-generation drugs
- The range of actionable mutations in NSCLC continues to increase and physicians are now able to find an agent to interact with the specific mutation of the patient
Recent Videos
Related Content
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024Article
In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
